Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo

Clinical and Experimental Allergy

Volumn 37, Issue 11, 2007, Pages 1648-1656

  Galatowicz, Grazyna ^a   Ajayi, Yetunde ^a   Stern, Michael E ^b   Calder, Virginia L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ALLERGAN INC   (United States)

Author keywords

Cytokines; Human mast cells; Seasonal allergic conjunctivitis

Indexed keywords

AZELASTINE; EPINASTINE; HISTAMINE; INTERLEUKIN 10; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; NEDOCROMIL SODIUM; OLOPATADINE; RAPITIL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL INFILTRATION; CONJUNCTIVA; CONJUNCTIVAL BIOPSY; CONTROLLED STUDY; CYTOKINE RELEASE; DEGRANULATION; DRUG MECHANISM; EOSINOPHIL; EOSINOPHIL COUNT; FEMALE; HISTAMINE RELEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-ALLERGIC AGENTS; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; CONJUNCTIVA; CONJUNCTIVITIS, ALLERGIC; CYTOKINES; DIBENZAZEPINES; DIBENZOXEPINS; EOSINOPHILIA; FEMALE; FETAL BLOOD; HISTAMINE RELEASE; HUMANS; IMIDAZOLES; MAST CELLS; MICE; MICE, INBRED BALB C; NEDOCROMIL; NEUTROPHILS; POLLEN; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, IGE; STEM CELLS;

EID: 35349027236     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2007.02782.x     Document Type: Article

References (29)

1. Kempuraj D, Huang M, Kandere K et al. Azelastine is more potent than olopatadine in inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Ann Allergy Asthma Immunol 2002 88 : 501 6.
2. Kempuraj D, Huang M, Kandere-Grzybowska K et al. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol 2003 132 : 231 9.
3. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005 65 : 215 28.
4. Kamei C, Akagi M, Mio M et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: Elucidation of the mechanism for histamine release inhibition. Immunopharmacol Immunotoxicol 1992 14 : 191 205.
5. Yamada Y, Sannohe S, Saito N et al. Effect of ketotifen on the production of reactive oxygen species from human eosinophils primed by eotaxin. Pharmacology 2003 69 : 138 41.
6. Woerly G, Loiseau S, Loyens M, Schoch C, Capron M. Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: consequences for allergic eye diseases. Allergy 2003 58 : 397 406.
7. Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM. Characterisation of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996 278 : 1252 61.
8. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits TNF-alpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol 2000 84 : 504 8.
9. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann Allergy Asthma Immunol 2001 87 : 424 9.
10. Hingorani M, Calder VL, Buckley RJ, Lightman S. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest Ophthalmol Vis Sci 1999 40 : 392 9.
11. Dahl C, Saito H, Nielsen HV, Schiotz PO. The establishment of a combined serum-free and serum-supplemented culture method of obtaining functional cord blood-derived human mast cells. J Immunol Methods 2002 262 : 137 43.
12. Magone MT, Chan CC, Rizzo LV, Kozhich AT, Whitcup SM. A novel murine model of allergic conjunctivitis. Clin Immunol Immunopathol 1998 87 : 75 84.
13. Stern ME, Siemasko K, Gao J et al. Role of interferon-gamma in a mouse model of allergic conjunctivitis. Invest Ophthalmol Vis Sci 2005 46 : 3239 46.
14. Morgan SJ, Williams JH, Walls AF, Church MK, Holgate ST, McGill JK. Mast cell numbers and staining characteristics in the normal and allergic conjunctiva. J Allergy Clin Immunol 1991 87 : 111 6.
15. Stahl JL, Cook EB, Graziano FM, Barney NP. Human conjunctival mast cells. Expression of FceRI, c-kit, ICAM-1 and IgE. Arch Opthalmol 1999 117 : 493 7.
16. Hundley TR, Gilfillan AM, Tkaczyk C, Andrade MV, Metcalfe DD, Beaven MA. Kit and FcεR1 mediate unique and convergent signals for the release of inflammatory mediators from human mast cells. Blood 2004 104 : 2410 7.
17. Nakagami T, Murakami A, Okisaka S, Ebihara N. Mast cells in pterygium: number and phenotype. Jpn J Ophthalmol 1999 43 : 75 9.
18. Vanapalli S, Yu D, Tang-Liu D. Analysis of epinastine tear concentration after topical ophthalmic administration. AAAAI Annual Meeting, 2005, abstract #519.
19. Brockman HL, Momsen MM, Knudtson JR et al. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul Immunol Inflamm 2003 11 : 247 268.
20. Easty D, Rice NS, Jones BR. Disodium cromoglycate (Intal) in the treatment of vernal keratoconjunctivitis. Trans Ophthalmol Soc UK 1971 91 : 491 9.
21. Gibbs BF, Haas H, Falcone FH et al. Purified human peripheral blood basophils release interleukin-13 and preformed interleukin-4 following immunological activation. Eur J Immunol 1996 26 : 2493 8.
22. Bradding P, Feather IH, Howarth PH et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992 176 : 1381 6.
23. Takeuchi K, Kishioka C, Ishinaga H, Sakakura Y, Majima Y. Histamine alters gene expression in cultured human nasal epithelial cells. J Allergy Clin Immunol 2001 107 : 310 4.
24. Muller T, Myrtek D, Bayer H et al. Functional characterization of histamine receptor subtypes in a human bronchial epithelial cell line. Int J Mol Med 2006 18 : 925 31.
25. Matsukura M, Yajima A, Yamazaki F, Yudate T, Yamada H, Tezuka T. Epinastine inhibits eosinophil chemotaxis and adhesion molecules in atopic dermatitis. Skin Pharmacol Appl Skin Physiol 2003 16 : 405 10.
26. Tasaka K. IL-8 release from eosinophils inhibited by epinastine (post-transcriptionally). Drugs Today (Barcelona) 2000 36 : 735 57.
27. + T cells in-vitro. J Pharm Pharmacol 2005 57 : 1027 36.
28. Kanai K, Asano K, Watanabe S, Kyo Y, Suzaki H. Epinastine hydrochloride antagonism against interleukin-4-mediated T cell cytokine imbalance in vitro. Intl Arch Allergy Immunol 2006 140 : 43 52.
29. 2+-dependent protein kinase C, Raf/MEK/ERK and IKK/IkB/NFkB signal cascades. Biochem Pharmacol 2005 69 : 433 49.